Nimbus Therapeutics is making Scott Edmondson, Ph.D., its new senior vice chairman and head of chemistry.
Edmondson comes from being director and head of Boston oncology chemistry at AstraZeneca, the place he oversaw recruiting, administration and strategic course for a staff of greater than 30 chemists. Earlier than this, he spent a mammoth 18 years over at U.S. Large Pharma Merck.
Now, he turns to the a lot smaller Cambridge, Massachusetts-based Nimbus. The digital biotech makes use of an in silico and computational chemistry platform to construct novel small molecules. It has a number of discovery partnerships with Large Pharma and biotech corporations, together with Gilead and its out-licensed nonalcoholic steatohepatitis drug.
Edmondson will now assist run Nimbus’ R&D, which incorporates 4 new applications it has been engaged on that would result in therapies for metabolic issues, most cancers and autoimmune illnesses. These embody CTPS1, an enzyme that performs a job in immune activation, and AMPKβ2, which regulates metabolic homeostasis in lots of tissues. The opposite two, WRN and Cbl-b, are each immuno-oncology targets. All 4 are troublesome to drug.
Nimbus will spend the following 12 months pushing these applications ahead with the aim of touchdown on improvement candidates. It’s additionally engaged on an IND for its HPK1 inhibitor in addition to taking its Tyk2 program right into a part 2b examine in 2021, the corporate just lately instructed Fierce Biotech.
“We’re delighted to welcome Scott to Nimbus at such an thrilling interval of development for the corporate,” mentioned Peter Tummino, Ph.D., chief scientific officer of Nimbus. “Scott’s intensive expertise at constructing and main world-class chemistry groups shall be extremely precious as we progress our discovery efforts and lay the groundwork for our subsequent technology of vital small molecule therapeutics.”
“I’m excited to affix this distinctive staff of drug hunters,” added Edmondson. “Nimbus’ distinctive place on the nexus of structural biology, computational chemistry and molecular sciences has pushed the corporate’s lengthy historical past of successes, and I’m keen to assist lead the invention efforts that can form the corporate’s promising future pipeline.”